Lv4
470 积分 2024-02-08 加入
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?
1个月前
已完结
Harnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy
1个月前
已完结
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
1个月前
已完结
Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis
1个月前
已完结
Real‐world evidence of cisplatin versus carboplatin in patients with locally advanced nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: A multicenter analysis
1个月前
已完结
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response
1个月前
已完结
Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma
1个月前
已完结
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
1个月前
已完结
皖公网安备34019202002308
